Which hospitals offer heavy ion therapy? (as of 2026)

Under Korean medical law, this guide cannot disclose specific hospital names or hospital-by-hospital outcomes; what the source notes do confirm is that heavy ion therapy in Korea is provided at domestic tertiary hospitals equipped with foreign-language care systems and international clinic centers.

Key Takeaways

• Heavy ion therapy (carbon-ion radiotherapy) uses accelerated carbon ions aimed at tumors, and according to National Cancer Center Korea materials, the first treatment in Korea began in 2023.
• Under Korean medical law, this guide cannot disclose specific hospital names or hospital-by-hospital outcomes.
• Eligible cases are localized solid tumors with defined indications, with prostate cancer, hepatocellular carcinoma, certain lung cancers, pancreatic cancer, and bone/soft-tissue sarcoma mentioned in the source notes.
• The treatment process is divided into a planning phase and an irradiation phase, with the irradiation phase delivered over multiple outpatient sessions per week, the number varying by cancer type.
• Recurrence at a site previously treated with radiotherapy may also be considered, but records of the prior irradiation site and dose are the key data used to determine eligibility.

Which hospitals offer heavy ion therapy?

• Under Korean medical law, this guide does not disclose specific hospital names or hospital-by-hospital outcomes. Heavy ion therapy equipment requires a facility the size of an entire building, so few centers operate it worldwide, and in Korea this treatment is provided at tertiary hospitals equipped with foreign-language care systems and international clinic centers.
• Korea's first domestic heavy ion treatment began in 2023, and according to the notes, additional facilities are being prepared since then. Which hospital is right for your specific cancer type and stage is a matter for medical staff to determine based on individual imaging and pathology records, and this informational guide alone cannot confirm or arrange a specific hospital.

How do I know if my cancer qualifies for heavy ion therapy?

• Solid tumors confined to one location are eligible, and cases such as prostate cancer, hepatocellular carcinoma, certain lung cancers, pancreatic cancer, and bone/soft-tissue sarcoma — where the tumor border is relatively well-defined and critical organs are nearby that must not be damaged — are reviewed for candidacy. Conversely, cancers that have spread to multiple organs, cancers that grow widely along the intestinal wall such as stomach or colorectal cancer, and blood cancers such as leukemia or lymphoma are not standard indications.
• In terms of staging, localized stages 1–3 are generally the ones reviewed, while stage 4 generally calls for systemic therapy to be considered first. Recurrence at a site previously treated with radiotherapy may also be considered, but in that case, records of the prior irradiation site and dose are essential. Actual applicability depends on each individual's tumor location, size, and treatment history, so consultation with the treating medical team is required.

What is the treatment sequence?

• Step 1: After arrival, a simulation CT/MRI scan is performed, and an immobilization device is made so the patient can maintain the same position every session.
• Step 2: The medical physics team and the radiation oncology department design and verify an irradiation plan tailored to the tumor's three-dimensional shape. This step is generally described as taking about 1–2 weeks.
• Step 3: The actual irradiation itself takes only a few minutes per session, with the number of sessions and weekly frequency varying by cancer type. In principle this is outpatient treatment, so patients commute daily from accommodation near the hospital.
• Step 4: Return home is possible within a few days after the final irradiation session, while whether the tumor has actually shrunk is confirmed through imaging over the following months. It is common for the tumor to still appear on imaging immediately after treatment, and this does not indicate failure.

FAQ — How is this different from proton therapy?

Both heavy ion therapy and proton therapy are classified as particle radiotherapy, but because carbon ions are heavier than protons, they cause stronger double-strand breaks in cancer cell DNA, which is why the notes explain that heavy ion therapy is also attempted on tumors that responded poorly to conventional X-ray radiation. In situations where protecting normal tissue matters most (pediatric patients, or tumors near the eyes/brain/spinal cord), proton therapy tends to be considered, whereas for radiation-resistant tumors, heavy ion therapy is reviewed — the key point is not that one is simply better, but finding the option that matches the patient's stage and tumor location.

FAQ — Is it still possible if I already received radiotherapy in another country?

Eligibility depends on the previously irradiated site and the total dose received. Prior radiotherapy records containing the irradiated site, total dose, number of fractions, and treatment dates are identified as the single most important data point for determining whether re-irradiation is possible, and the notes state clearly that without this record, suitability for re-irradiation is difficult to assess. The final determination must be made by the treating medical team after reviewing these records.

Sources and notes

• This guide was prepared based on notes on heavy ion therapy and proton therapy (National Cancer Center Korea's National Cancer Information Center, and NCCN patient guidelines).
• This content is intended to provide general medical information, and actual diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Please consult with your medical team to determine an accurate diagnosis and treatment plan.